⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20844157 | 0.79 | — | — | |
| SCHEMBL15759816 | 0.79 | — | — | |
| SCHEMBL18985908 | 0.75 | — | — | |
| SCHEMBL16381981 | 0.75 | — | — | |
| SCHEMBL9967437 | 0.75 | — | — | |
| SCHEMBL623346 | 0.75 | — | — | |
| SCHEMBL12031658 | 0.75 | — | — | |
| SCHEMBL22445300 | 0.75 | — | — | |
| SCHEMBL12131482 | 0.75 | — | — | |
| SCHEMBL17533890 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-12109198-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240139163-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2024-05-02 | — | — | US | disclosed |
| CN-114144230-B | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | 弗尔康医疗公司 | 2024-04-23 | — | — | CN | disclosed |
| EP-4219461-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | Medshine Discovery Inc. (CN) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023088425-A1 | 15-PGDH INHIBITOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2023078461-A1 | HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2023-05-11 | — | — | WO | disclosed |
| EP-4166551-A1 | TRIAZOLONE COMPOUND | Medshine Discovery Inc. (CN) | 2023-04-19 | — | — | EP | disclosed |
| US-11590111-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220160686-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
| CN-114144230-A | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | 弗尔康医疗公司 | 2022-03-04 | — | — | CN | disclosed |
| EP-3938050-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| WO-2021238881-A1 | TRIAZOLONE COMPOUND | 南京明德新药研发有限公司 | 2021-12-02 | — | — | WO | disclosed |
| US-10973805-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10973805-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200360353-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-20200360353-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2020-11-19 | — | — | US | disclosed |
| WO-2020190754-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. (US) | 2020-09-24 | — | — | WO | disclosed |
| EP-2205590-B1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-06-04 | — | — | EP | disclosed |
| WO-2012064808-A1 | TETRAZOLYL - TETRAHYDROPYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE - RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2012-05-18 | — | — | WO | disclosed |